General and Electrophysiological Toxic Effects of Manganese in Rats following Subacute Administration in Dissolved and Nanoparticle Form by Horváth, Edina et al.
The Scientific World Journal
Volume 2012, Article ID 520632, 7 pages
doi:10.1100/2012/520632
The cientificWorldJOURNAL
Research Article
General and Electrophysiological Toxic Effects of
Manganese in Rats following Subacute Administration in
Dissolved and Nanoparticle Form
Edina Horva´th,1 Zsuzsanna Ma´te´,1 Szabolcs Taka´cs,1 Pe´ter Pusztai,2 Andra´s Sa´pi,2
Zolta´n Ko´nya,2 La´szlo´ Nagymajte´nyi,1 and Andra´s Papp1
1Department of Public Health, University of Szeged Faculty of Medicine, Do´m te´r 10., 6720 Szeged, Hungary
2Department of Applied Chemistry, University of Szeged Faculty of Science and Informatics, Rerrich Be´la te´r 1.,
6720 Szeged, Hungary
Correspondence should be addressed to Edina Horva´th, korosine.edina@med.u-szeged.hu
Received 14 October 2011; Accepted 5 December 2011
Academic Editors: N. Futrakul and J. L. Labandeira-Garcı´a
Copyright © 2012 Edina Horva´th et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
In an attempt to model occupational and environmental Mn exposures and their possible interaction, young male Wistar rats
were exposed to Mn by oral administration in dissolved form (MnCl2·4H2O, 14.84 and 59.36mg/kg b.w.) and by intratracheal
application ofMnO2 nanoparticles (2.63mg/kg b.w.). After 3 and 6 weeks oral, or 3 weeks oral plus 3 weeks intratracheal, exposure,
general toxicological, and electrophysiological tests were done. Body weight gain was significantly reduced after 6 and 3 plus 3
weeks exposure, but the eﬀect of the latter on the pace of weight gain was stronger. Organ weights signalized systemic stress and
eﬀect on lungs. Changes in evoked electrophysiological responses (cortical sensory evoked potential and nerve action potential)
indicated that the 3 plus 3 weeks combined exposure caused equal or higher changes in the latency of these responses than 6 weeks
of exposure, although the calculated summed Mn dose in the former case was lower. The results showed the importance of the
physicochemical form of Mn in determining the toxic outcome, and suggested that neurofunctional markers of Mn action may
indicate the human health eﬀect better than conventional blood Mn measurement.
1. Introduction
It has been recognized in the last ca. 20 years that people’s
exposure to nanoparticles (NPs)s—let them be pollutants
or components in nanotechnological products—has major
influence on health. NPs are, by definition, particles which
measure less than 100 nm in all three directions. In this size
range, the surface-to-mass ratio becomes extremely high,
meaning that this particle fraction (also called ultrafine dust)
represents only a small mass fraction in any (environmental
or occupational) dust sample but a high number of particles
with a very high and reactive overall surface [1]. The small
size also means that, once absorbed, NPs have extreme
mobility within the (animal or human) organism and can
reach all parts of it by crossing conventional barriers such as
the alveolar or capillary wall. This, and the inflammogenic
nature of NPs, is strongly influenced by their surface charac-
teristics [2].
Concerning manganese (Mn), both fine and ultrafine
particles containing this metal are likely generated in various
phases of production and processing of Mn, from ore mining
through steel casting and welding to the production of
dry batteries; so that particle inhalation is a major way
of—primarily occupational—exposure to this metal. The
human nervous system eﬀects of chronic Mn exposure are
manifested by a state called manganism, a set of symptoms
that is similar to Parkinson’ disease and appears frequently in
welders inhaling metal fumes [3]. Such exposure is typically
job-related (but see [4]) while the general public might
experience particulate Mn inhalation due to the use of
methylcyclopentadienyl manganese tricarbonyl (MMT) as
an antiknock petrol additive in some countries [5].
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Manganese-induced Parkinsonism was, however, also
observed in patients undergoing maintenance hemodialysis
[6] or in inadvertent overdosing due to long-term ingestion
of a health supplement containing high levels of Mn, which
indicates that other physicochemical forms of Mn and other
routes of exposure are also relevant to the health of the
CNS. For geological reasons (e.g., in Greece [7]) or due
to man-made pollution (such as improper disposal of used
dry cells in Japan [8]) abnormally high Mn levels in the
drinking water were observed, together with CNS symptoms
of the aﬀected population. In regions of the USA with
high-Mn drinking water, loss of visual and verbal memory,
typical forMn-induced brain damage, was described [9]. The
neurotoxic spectrum of Mn is variable: epileptic activity was
observed in children following inhalational Mn exposure [4]
or prolonged total parenteral nutrition [10], and alterations
in EEG and evoked potential were seen in shipyard workers
[11].
Based on the above literature data, indicating the rel-
evance of both inhalational and oral exposure by Mn to
nervous system eﬀects, the present study was aimed at
investigating the adverse neurofunctional eﬀects in rats,
caused byMn in diﬀerent physicochemical forms (by inhaled
Mn NPs and by dissolved Mn taken up orally). Our goal
was to create an experimental model reproducing complex
human Mn exposure—including occupational and nutri-
tional sources—more adequately, and to detect the eﬀects
by electrophysiological methods, the suitability of which was
proven in previous works [12, 13].
2. Materials and Methods
2.1. Animals and Treatment. Young adult male Wistar rats (7
weeks old, body weight 200 ± 20 g) were obtained from the
breeding centre of the university and were housed in a GLP-
rated animal house (22 ± 1◦C, 30–60% relative humidity,
12 h light/dark cycle with light on at 06:00), with free access
to tap water and standard pellet (at start, there were 12
groups of 12 rats each; this number allowed for eventual
losses during treatment, finally 8 rats per group were chosen
randomly for evaluation).
Treatments, representing oral and inhalational exposure,
were performed once daily, 5 times a week, and lasted alto-
gether 3 or 6 weeks (see Table 1 for group codes, doses, and
treatment times). The oral doses were based on an earlier
work of us [14] where 14.84 and 59.36mg/kg b.w. of MnCl2
were given by gavage for several weeks. The intratracheal
dose of 2.63mg/kg b.w. of MnO2 NPs was likewise tested in
a previous experiment [12].
For oral application, manganese chloride (MnCl2 4H2O;
Reanal, Hungary; purity 99.5%) was dissolved in distilled
water to 1mL/kg b.w. administration volume and was given
to the rats by gavage. The NPs used for intratracheal appli-
cation consisted of MnO2, had 23.2 ± 3.3 nm diameter, and
were synthesized at the Department of Applied Chemistry,
University of Szeged by a technique combining sonication
and hydrothermal treatment (see [13] for details). The
NPs were suspended in 1% hydroxyethyl cellulose (HEC)
Table 1: Treatment scheme with group codes, doses and treatment
times.
Group code Treatment and dose
C3 3 weeks, untreated
VC3 3 weeks, distilled water, orally
MnL3 3 weeks 14.84mg/kg b.w. MnCl2, orally
MnH3 3 weeks 59.36mg/kg b.w. MnCl2, orally
C33 6 weeks, untreated∗
VC33
3 weeks, distilled water, orally + 3 weeks HEC
intratracheally
MnL33
3 weeks 14.48mg/b.w. kg MnCL2, orally + 3 weeks
MnO2 NPs 2.63mg/kg b.w. intratracheally
MnH33
3 weeks 59.36mg/b.w. kg MnCL2, orally + 3 weeks
MnO2 NPs 2.63mg/kg b.w. intratracheally
C6 6 weeks, untreated∗
VC6 6 weeks, distilled water, orally
MnL6 6 weeks 14.84mg/kg b.w. MnCl2, orally
MnH6 6 weeks 59.36mg/kg b.w. MnCl2, orally
∗
C33 and C6 were two diﬀerent groups of rats.
Table 2: Body weight gain of the rats during the treatment period.
Group Body weight gain (g)
Summed Mn dose
(mgMn◦/animal)
C3 161.7 ± 14.4 —
VC3 149.9 ± 11.2 —
MnL3 149.2 ± 13.9 (99.6%) 17.94 ± 0.52
MnH3 143.7 ± 23.6 (95.9%) 71.58 ± 2.93
C33 234.2 ± 19.7 —
VC33 218.4 ± 20.9 —
MnL33 210.9 ± 17.2∗ (96.5%) 28.46 ± 0.55
MnH33 195.2 ± 27.6∗∗# (89.4%) 83.42 ± 2.95
C6 234.2 ± 25.0 —
VC6 235.2 ± 15.3 —
MnL6 226.1 ± 17.3 (96.2%) 44.55 ± 1.00
MnH6 211.0 ± 19.3# (89.7%) 178.43 ± 8.53
For group codes, see Table 1. The data represent group averages (mean ±
SD, n = 8) of the diﬀerence between body weight on day 0 (before the first
Mn administration) and the day of sacrifice.
∗, ∗∗: P < 0.05, 0.01 versus C; #: P < 0.05 versus VC.
Percent values in parentheses represent the weight gain in the Mn-treated
groups compared to that in the corresponding VC group.
dissolved in PBS (pH 7.4) to have a physiologically neutral
vehicle in which unwanted surface interactions of the NPs
were unlikely. The nanosuspension was instilled in the rats’
trachea in brief diethyl ether anaesthesia (see [12] for details).
The instilled volume was 1.0mL/kg b.w. The summed dose
(see Table 2) was calculated by adding theMn◦ content of the
daily administered volumes which were based on the daily
body weights and the above-mentioned per kg doses.
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2.2. General Toxicological Investigation. Body weight of the
animals was measured before every treatment, for followup
and for calculating the exact doses to be administered that
day. Growth curves were plotted and the weight gain over the
whole treatment period was determined. Following electro-
physiological recording (the last phase of the investigations)
the rats used were sacrificed by an overdose of urethane (the
anesthetic used in electrophysiology), were dissected, and
organ weights were measured. Relative organ weights, as a
routine index of toxicity, were calculated on the basis of brain
weight. This was chosen so (using the rationale described
in [15]) because the brain weight was not significantly
diﬀerent among the groups while body weight, the other
usual calculation basis, showed some significant changes (see
Table 2).
2.3. Electrophysiological Investigation. Electrophysiological
recording was done on the day following the last Mn
administration. Preparation for recording, and the recording
itself, was performed in urethane anaesthesia (1000mg/kg
i.p.) on 8 rats per group. The left hemisphere was surgically
exposed (lidocaine spray was applied on the wounds) and
spontaneous electrical activity (electrocorticogram, ECoG)
was recorded from the primary somatosensory (SS), visual
(VIS) and auditory (AUD) areas for 6 minutes using
ball-tipped silver wire surface electrodes. From this, band
spectrum according to the standard human EEG bands (delta
to gamma [16]) was calculated. Then, evoked potentials
(somatosensory, visual, and auditory) were recorded from
the same sites by applying sensory stimuli in trains of 50.
Somatosensory stimulation was done by square pulses
(3-4 V; 0.05ms; 1, 2 and 10Hz frequency) delivered through
a pair of needles inserted into the contralateral whiskery skin.
Visual stimulation was performed by flashes (1Hz) of a high-
luminance white LED placed to the contralateral eye of the
rat. For acoustic stimulation, clicks (1Hz) were applied to the
contralateral ear through the hollow ear bar of the stereotaxic
frame. Onset latency and duration of the EPs was measured
after averaging the 50 individual records. From the tail nerve,
compound action potential was recorded by inserting a pair
of needle electrodes at the base of the tail for stimulation,
and another pair 50mm distally for recording. Conduction
velocity was calculated from this distance and the onset
latency of the action potential. Relative refractory period
was measured by double stimuli with 1–10ms interstimulus
interval, from the extra delay of the second potential. The
complete electrophysiological work was performed by means
of the software Neurosys 1.11 (Experimetria Ltd., Budapest,
Hungary).
During the whole course of the experiment, the princi-
ples of the Ethical Committee for the Protection of Animals
in Research of the University were strictly followed.
2.4. Statistical Evaluation. The distribution of data was
checked for normality by means of the Kolmogorov-Smirnov
test. Data analysis was done by one-way ANOVA. Post hoc
analysis of group diﬀerences was performed by LSD test,
setting the probability level at P > 0.05.
3. Results
3.1. Body and Organ Weights. Oral Mn exposure caused
only a light, nonsignificant reduction in the treated rats’
body weight gain after 3 weeks, and after 6 weeks with the
lower dose. Only after 6 weeks and the higher dose (MnH6)
did weight gain show significant reduction. Where, how-
ever, intratracheal exposure followed the oral one (MnL33,
MnH33) the reduction of weight gain was always significant.
Compared to the corresponding controls, reduction of
weight gain was somewhat stronger in the group MnH33
than in MnH6, although the calculated summed Mn dose
was much lower in MnH33 than in MnH6 (Table 2). This
suggested a potentially more eﬃcient absorption of Mn from
the airways than from the gastrointestinal tract. It is also
noteworthy that in VC33 the weight gain reduction versus the
corresponding untreated control was moderate (although
present), indicating that the procedure of intratracheal
administration itself (including repeated etherization) had
no significant general toxic eﬀect. The graph in Figure 1(a)
shows the time course of weight gain (with an abrupt change
at the beginning of intratracheal application of Mn NPs, but
not of vehicle alone) while Figure 1(b) demonstrates that the
individual rats’ daily weight gain was more aﬀected in the
oral + intratracheal treatment groups in spite of the lower
summed dose.
Among the relative organ weights, that of the lung, liver
and adrenals showed significant changes (Table 3; the table
also lists the absolute data of brain weight to show the basis of
calculation). Lung weight was strongly aﬀected by the intra-
tracheal Mn treatment (MnL33, MnH33) and less strongly
also by the intratracheal vehicle administration (VC33). The
lungs excised from rats with intratracheal Mn exposure
had typically an emphysematic appearance with visible dark
spots of Mn deposition.
3.2. Electrophysiological Eﬀects. There were no prominent
changes in the spontaneous cortical activity. A trend of
decreased power in the low-frequency (delta, and to a lesser
extent, theta) bands, and increase in the fast beta2 and
gamma bands was observed in all three cortical areas but
without significance.
On the sensory EPs, Mn treatment generally caused a
latency increase. As seen in Figure 2, SS EP latency was
universally increased in the treated rats versus vehicle con-
trol. At the same time, the latency was also influenced by
the frequency of stimulation, and this frequency-dependent
lengthening was in the treated groups also typically more
intense. Figure 2 also shows that latency increase in MnL33
was about equal to that in MnL6 at all stimulation frequen-
cies, and also in MnH33 to MnH6 at 1 and 2Hz stimulation;
a relationship similar to that seen with the body weight gain
(see Figure 1(b) and Table 2).
The latency of VIS and AUD EPs was also lengthened by
Mn exposure (Figure 3) but the relationship of the groups
with 3 weeks oral + 3 weeks intratracheal versus 6 weeks oral
treatment was not like in case of the SS EP. In case of all three
sensory modalities, however, within one treatment variation
the higher dose caused more lengthening of the latency:
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Figure 1: (a) Time course of the control and treated rats’ weight gain in the 3 weeks oral + 3 weeks intratracheal and the 6 weeks oral
treatment. Mean ± SD, n = 8. Significance marking omitted for clarity; for this, see Table 2. (b) Relationship of summed Mn dose (abscissa)
and daily weight gain (ordinate) of individual rats belonging to the treatment groups given in the insert. Daily weight gain was calculated by
dividing total weight gain with the length of treatment.
Table 3: Relative organ weights of the lungs, liver, and adrenals, and the absolute brain weights used as calculation basis.
Groups Brain absolute weight (g)
Relative organ weights
Lungs Liver Adrenals
C3 1.989 ± 0.061 0,170 ± 0.009 1,856 ± 0.104 0,0070 ± 0.0010
VC3 1,999 ± 0.072 0,200 ± 0.021∗ 1,606 ± 0.103∗ 0,0085 ± 0.0027
MnL3 2,038 ± 0.095 0,167 ± 0.017# 1,837 ± 0.207# 0,0070 ± 0.0008
MnH3 1,974 ± 0.111 0,224 ± 0.055∗X 1,840 ± 0.299 0,0081 ± 0.0011X
C33 2,076 ± 0.061 0,169 ± 0.020 1,534 ± 0.101 0,0061 ± 0.0013
VC33 2,092 ± 0.067 0,214 ± 0.009∗∗ 1,563 ± 0.113 0,0062 ± 0.0007
MnL33 2,053 ± 0.043 0,391 ± 0.056∗∗∗### 1,626 ± 0.133 0,0078 ± 0.0014∗#
MnH33 2,106 ± 0.077 0,372 ± 0.018∗∗∗### 1,450 ± 0.075#X 0,0073 ± 0.0014∗
C6 2,127 ± 0.047 0,151 ± 0.013 1,512 ± 0.102 0,0057 ± 0.0006
VC6 2,092 ± 0.028 0,154 ± 0.013 1,443 ± 0.088 0,0064 ± 0.0014
MnL6 2,124 ± 0.076 0,149 ± 0.011 1,546 ± 0.081 0,0070 ± 0.0009∗
MnH6 2,103 ± 0.060 0,165 ± 0.022 1,430 ± 0.106 0,0063 ± 0.0008
For group codes, see Table 1; for the calculation, see Section 2. The data are mean ± SD (n = 8).
∗, ∗∗, ∗∗∗: P < 0.05, 0.01, 0.001 versus C; #, ###P < 0.05, 0.001 versus VC; X: P < 0.05 MnH versus MnL.
an indication of dose dependence, an exception being
MnH33 versus MnL33 in case of SS EP. The duration of EPs
showed no consistent alteration.
The conduction velocity of the tail nerve was reduced
in the treated rats. As seen in Figure 4(a), this eﬀect was
also dose dependent, and the eﬀect in the group MnL33
was stronger than that seen in MnL6. The relative refractory
period of the tail nerve (Figure 4(b)) was also significantly
altered by Mn application.
4. Discussion
The most conspicuous result of the above experiments
was the disproportionately strong eﬀect seen with oral +
intratracheal combined Mn exposure. That is, the change
in body weight gain and in several electrophysiological
parameters was more, or at least not less, expressed in
the groups MnL33 and MnH33 (oral + intratracheal) than
in MnL6 and MnH6 (oral only), although in the latter
the applied summed dose was much higher (Table 2). This
pointed to possible diﬀerences in the absorption and/or to
qualitative diﬀerences in the toxicity of the two forms of Mn.
From the intestinal system, Mn is absorbed to only 10–
15% [5, 17]. This is the physiological way of covering Mn
demand so it is a regulated process where Mn overload leads
to decreased absorption rate. From the airways, however,
the absorption of NPs can be much more eﬃcient. NPs
translocate readily to extrapulmonary sites by a mechanism
involving transcytosis (caveola formation) across epithelia of
the respiratory tract into the interstitium, with subsequent
access to the blood and distribution throughout the body
[1]. Mn containing NPs can reach the brain from the blood
through the capillary endothelial cells in the blood-brain
barrier, and through the choroid plexuses [18]. Inhaled Mn
absorbed this way is likely to reach its target sites before
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Figure 2: Latency of the somatosensory evoked potential in the
control and treated rats, recorded with 1, 2, and 10Hz stimulation
frequency (see insert). Mean + SD, n = 8. The data displayed are
relative, calculated to the value obtained from the vehicle-treated
rats at 1Hz frequency as basis of comparison.∗, ∗∗, ∗∗∗: P < 0.05,
0.01, 0.001 treated versus VC; #, ##: P < 0.05, 0.01 MnL33 versus
MnL6; ◦, ◦◦, ◦◦◦: 2Hz or 10Hz stimulation versus 1Hz, within one
treatment group.
biliary excretion, the main mechanism of eliminating excess
Mn from the organism [19]. In a more direct way, Mn-
containing NPs enter the sensory nerve endings embedded
in the epithelia of the airways (primarily, but not exclusively,
in the olfactory mucosa) and migrate transsynaptically up to
the brain [20].
Even if there was no tissue Mn level measurement in the
present work, organ Mn load data of previous experiments
with the same doses and routes of application [12–14]
favor the reasoning that, on the basis of the observed toxic
eﬀects, inhaled NPs cause internal exposure more eﬃciently
than ingested, dissolved Mn. An alternative, equally feasible
explanation is that NPs had higher potency in inducing
oxidative stress than dissolved Mn, keeping in mind that
the surface chemistry of various oxide NPs is favorable for
inducing oxidative stress [1].
Oxidative stress, first of all, contributed probably to the
lung eﬀects. Welding fumes containing Mn were reported to
cause oxidative stress and inflammation [21]. In the liver,
weight decrease was seen in rats with oral + intratracheal
(MnL33, MnH33) exposure, but not in those receiving oral
exposure only. A similar eﬀect of NPs on the liver was seen
also previously (with Mn NPs: Oszla´nczi et al. [13]; but also
with Cd NPs: Horva´th et al. [22]). The dependence of the
eﬀect more on the nanoparticulate character than on the
chemical composition is supported by literature data on in
vivo liver damage related to oxidative stress in rats treated
with intratracheal TiO2 NPs [23], and oxidative damage of
in vitro human hepatic cells on exposure to ZnO NPs [24].
The decreased body weight gain in rats exposed to Mn NPs
(oral + intratracheal treatment: groups MnL33 and MnH33)
is also an indication of stress (as suggested in [25]) especially
in combination with the increased weight of the adrenals
in these groups (see Tables 2 and 3). Mn-induced systemic
oxidative stress has been reported to act also in the brain
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Figure 3: Latency of the visual (a) and auditory (b) evoked
potentials in the control and treated rats. Mean + SD, n = 8.
The relative data were calculated as given at Figure 2. ∗, ∗∗, ∗∗∗:
P < 0.05, 0.01, 0.001 treated versus VC; ##: P < 0.01 MnL33 versus
MnL6.
and contribute to functional alterations [26]. Astrocytes were
found to suﬀer oxidative damage on in vitro Mn exposure
[27]. Others, however, found no connection between Mn
neurotoxicity and ROS generation [28].
At the level of neurons, energetic shortage caused by
Mn-dependent inhibition of mitochondrial complex II [29]
and complex III [30] may lead to hypofunction of ion
pumps and/or disturbed turnover of transmitters, and
so to weakened propagation of the excitation. Increased
frequency-dependent lengthening of the SS EP latency in
treated versus control rats (see Figure 2) may be due to that.
The mentioned mechanism of action was probably present
not only on the cortical and subcortical level but along
the whole sensory pathway because the pulse conduction
velocity of the tail nerve (primarily of its fast myelinated
axons, largely contributing to the recorded compound action
potential and being especially sensitive to ATP depletion
[31])—and, even more importantly, the relative refractory
period, an indicator of the interaction of successive excitation
processes—was also aﬀected. Removal of glutamate from
the synaptic cleft is slowed by the direct eﬀect of elevated
extracellular Mn level [32] and indirectly by the blocking
eﬀect of Mn-induced ROS on the high-aﬃnity glutamate
transporters [33]. Accumulation of excess glutamate at all
transmission sites of the ascending sensory pathways may
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Figure 4: Changes of the nerve conduction velocity (a) and relative
refractory period (b) in the tail nerve of the rats. Mean + SD, n = 8.
The relative data were calculated as given at Figure 2. ∗, ∗∗, ∗∗∗:
P < 0.05, 0.01, 0.001 treated versus VC; #: P < 0.05, 0.01 MnL33
versus MnL6.
have resulted, after several weeks of Mn exposure, in
receptor desensitization, another factor leading to increased
EP latency [34]. The excitotoxic eﬀect of excess glutamate
cannot be ruled out either.
The results confirm the general and neurological toxicity
of both forms of Mn applied, and emphasize the higher
toxic potential of Mn-containing NPs as opposed to the
dissolved form. Both of these forms, however, can cause
human exposure, separately and simultaneously, and our
present results potentially suggest that preceding (or con-
current) oral Mn burden may increase the sensitivity to
inhaled Mn. This problem deserves further investigation, for
example, in model systems similar to ours—partly because
exposure from several sources or by several ways is a real-
life possibility, and partly because Mn level in human
biological samples is apparently not a reliable indicator of
CNS damage [35] and, not less importantly, is not sensitive
to the physicochemical form of the absorbed Mn. So,
eventual development of neurofunctional biomarkers, based
for example on the electrophysiological eﬀects examined in
this work, may be of importance—primarily in contributing
to sensitivity while Mn specificity will have to be provided by
other, probably chemical, markers.
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